Plain-English translation of NCT06151262 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Pancreatic Cancer research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This clinical trial is testing trilaciclib, a new medication designed to protect your bone marrow (which makes blood cells) during chemotherapy treatment. You would receive trilaciclib along with a standard chemotherapy combination called mFOLFIRINOX. The study wants to see whether the medication can reduce or prevent the blood cell problems that often happen during cancer treatment.
Chemotherapy saves lives but often damages the bone marrow, leading to low blood cell counts, infections, and other serious side effects. This medication is being studied to see if it can protect your bone marrow and make chemotherapy safer and easier to tolerate.
You likely qualify if…
You likely don't qualify if…
You would visit the hospital or clinic every 2 weeks for treatment visits. At each visit, you would receive the new medication (trilaciclib) by IV infusion, followed by the standard chemotherapy drugs, also given by IV. This cycle would repeat 12 times over about 6 months. During this time, you would have regular blood tests to monitor your blood cell counts and organ function, and your doctors would watch carefully for any side effects.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
China